In Focus: GioTag
The GioTag study investigated TKI sequencing in real-world patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who develop T790M. The final data confirmed those of previous analyses and demonstrated that sequential afatinib followed by osimertinib is a feasible and effective therapeutic strategy.
In our latest In Focus feature, learn more about the GioTag study design and concept and hear the authors explain the results in their own words.
Take a look at the abstract for the final GioTag article, which summarises the key conclusions that can be taken from the data and briefly describes the methods used.
Check out the infographic to visualize the GioTag’s study concept, and key design aspects and results.
Read the plain language summary to gain insights into the final results obtained from the study.